105 related articles for article (PubMed ID: 38719675)
1. Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up.
Wang HT; Chiu CF; Yang HR; Jeng LB; Bai EJ; Chen TH; Yeh CC; Chu CL; Bai LY
J Formos Med Assoc; 2024 May; ():. PubMed ID: 38719675
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
3. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
Yen CC; Shan YS; Chao YJ; Liao TK; Chen IS; Huang HY; Liu IT; Yen CJ
BMC Cancer; 2021 Jul; 21(1):796. PubMed ID: 34243732
[TBL] [Abstract][Full Text] [Related]
4. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
Deng W; Wang QW; Zhang XT; Lu M; Li J; Li Y; Gong JF; Zhou J; Lu ZH; Shen L
World J Gastroenterol; 2014 Mar; 20(12):3356-63. PubMed ID: 24696615
[TBL] [Abstract][Full Text] [Related]
6. Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study.
Lee CM; Yoo MW; Son YG; Oh SJ; Kim JH; Kim HI; Park JM; Hur H; Jee YS; Hwang SH; Jin SH; Lee SE; Park JH; Seo KW; Park S; Kim CH; Jeong IH; Lee HH; Choi SI; Lee SI; Kim CY; Kim IH; Son MW; Pak KH; Kim S; Lee MS; Min JS
J Gastric Cancer; 2020 Jun; 20(2):152-164. PubMed ID: 32595999
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
8. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
9. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Yen HH; Chen CN; Yeh CC; Lai IR
World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
[TBL] [Abstract][Full Text] [Related]
11. A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial.
Nishikawa K; Murotani K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Hasegawa H; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Cancer Chemother Pharmacol; 2019 May; 83(5):867-874. PubMed ID: 30806758
[TBL] [Abstract][Full Text] [Related]
12. Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan.
Yamada Y; Kobayashi H; Nagashima K; Sugihara K
Glob Health Med; 2022 Oct; 4(5):259-267. PubMed ID: 36381569
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
16. Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer.
Kusumoto T; Ishiguro M; Nakatani E; Yoshida M; Inoue T; Nakamoto Y; Shiomi A; Takagane A; Sunami E; Shinozaki H; Takii Y; Maeda A; Ojima H; Hashida H; Mukaiya M; Yokoyama T; Nakamura M; Munemoto Y; Sugihara K
ESMO Open; 2018; 3(6):e000428. PubMed ID: 30425843
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis.
Quan R; Huang J; Chen H; Liao Y; Lv W; Chen N; Liu J; Zhang H; Xu D
Oncotarget; 2016 Nov; 7(46):76316-76326. PubMed ID: 27602756
[TBL] [Abstract][Full Text] [Related]
19. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
20. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]